

ALZHEIMER'S DISEASE

Fax requests to (902) 368-4905 **OR** mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8

SECTION 1 - PATIENT INFORMATION

PERSONAL HEALTH NUMBER (PHN)		PATIENT (FAMILY) NAME	PATIENT (GIVEN) NAME(S)
DATE OF BIRTH (YYYY/MM/DD)	PATIENT WEIGHT (kg)	PATIENT'S MAILING ADDRESS	

SECTION 2 - PRESCRIBER INFORMATION

NAME AND MAILING ADDRESS	APPLICATION DATE YYYY MM DD
	PRESCRIBER'S TELEPHONE # AREA CODE
	PRESCRIBER'S FAX # AREA CODE

SECTION 3 - MEDICATION DETAIL INFORMATION

REQUESTED DRUG (PLEASE CHECK ONE) <input type="checkbox"/> Donepezil (Aricept) <input type="checkbox"/> Galantamine (Reminyl) <input type="checkbox"/> Rivastigmine (Exelon)	DOSAGE AND FREQUENCY
CAUSE OF PATIENT'S DEMENTIA (check relevant boxes below): <input type="checkbox"/> Probable Alzheimer's disease; <input type="checkbox"/> Probable Alzheimer's disease with vascular component; <input type="checkbox"/> Probable Alzheimer's disease with Lewy bodies; <input type="checkbox"/> Probable Alzheimer's disease with other (please specify); - Current MMSE score is (must be within 90-days of application): _____ Date: _____ - Previous MMSE score was: _____ Date: _____ - Patients less than 65 years of age will require a written consultation from a neurologist or geriatrician supporting the diagnosis and treatment. A copy of the consultation must be included with the Special Authorization Request.	
TYPE OF COVERAGE REQUESTED (check relevant boxes below): <input type="checkbox"/> Request for an initial 90-day trial of a cholinesterase inhibitor. <input type="checkbox"/> Request for a second 90-day trial using a second cholinesterase inhibitor. - Please identify the previous cholinesterase inhibitor: _____ Date started: _____ - Reason a previous cholinesterase inhibitor was discontinued: <input type="checkbox"/> Important deterioration in dementia symptoms <input type="checkbox"/> Drug interactions <input type="checkbox"/> Gastrointestinal side-effects <input type="checkbox"/> Drug-disease interactions <input type="checkbox"/> Syncope <input type="checkbox"/> Sleep disturbances <input type="checkbox"/> Delirium <input type="checkbox"/> Other (specify): _____	
OR <input type="checkbox"/> Request for continued coverage of a cholinesterase inhibitor. Date started: _____	

PEI Pharmacare may request additional documentation to support this Special Authorization Request. Personal information on this form is collected under section 31(c) of Prince Edward Island's Freedom of Information & Protection of Privacy (FOI/PP) Act as it relates directly to and is necessary for providing services under the PEI High-Cost Drugs Program.	
If you have any questions about this collection of personal information, you may contact the program office at 902-368-4947 or at the address at the top of the form.	
PRESCRIBER SIGNATURE (REQUIRED)	DATE

11HPE15-30346